Insider Transactions in Q1 2024 at Syros Pharmaceuticals, Inc. (SYRS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2024
|
Nancy A Simonian |
BUY
Exercise of conversion of derivative security
|
Direct |
45,566
+13.35%
|
-
|
|
Mar 31
2024
|
Kristin Stephens Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,666
+19.24%
|
-
|
|
Mar 31
2024
|
Jason Haas Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,333
+21.21%
|
-
|
|
Mar 31
2024
|
David Roth Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,333
+48.26%
|
-
|
|
Mar 31
2024
|
Conley Chee President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,666
+21.61%
|
-
|
|
Mar 28
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Payment of exercise price or tax liability
|
Direct |
7,046
-15.05%
|
$35,230
$5.59 P/Share
|
|
Mar 27
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+32.47%
|
-
|